Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05966090 · ClinicalTrials.gov registry record · Phase 3
A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults
A Phase 3 study of Respiratory Syncytial Virus Infections and Respiratory Syncytial Viruses, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 530
- Enrollment target
- 20
- Study locations
NCT05966090 is a Phase 3 study of Respiratory Syncytial Virus Infections and Respiratory Syncytial Viruses that has completed, run by GlaxoSmithKline. The registered enrollment target is 530 participants, below the 1,066-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (50% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT05966090, a Phase 3 study of Respiratory Syncytial Virus Infections and Respiratory Syncytial Viruses, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 530 participants
- Enrollment target
- 20
- Study locations
Study Summary
To assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with HZ/su vaccine and its safety in older adults, aged \>=50 years of age.
Conditions Studied
Interventions
- BIOLOGICAL RSVPreF3 OA investigational vaccine
- BIOLOGICAL HZ/su vaccine
Study Locations (20)
Quebec
- GSK Investigational Site - Québec
- GSK Investigational Site - Québec
- GSK Investigational Site - Québec
- GSK Investigational Site - Québec
- GSK Investigational Site - Sherbrooke
Ontario
- GSK Investigational Site - Brampton
- GSK Investigational Site - Guelph
- GSK Investigational Site - Toronto
- GSK Investigational Site - Toronto
Florida
- GSK Investigational Site - North Miami Beach
- GSK Investigational Site - West Palm Beach
Texas
- GSK Investigational Site - Fort Worth
- GSK Investigational Site - San Antonio
Alabama
- GSK Investigational Site - Daphne
Arizona
- GSK Investigational Site - Tempe
California
- GSK Investigational Site - Corte Madera
Colorado
- GSK Investigational Site - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2023-07-28 |
| Est. Completion | 2024-07-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05966090
The ClinicalTrials.gov registry entry for NCT05966090 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 530 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,066-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (50% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Respiratory Syncytial Virus Infections appearing as the primary indexed condition, and to 2 interventions - of which RSVPreF3 OA investigational vaccine is the first listed.
NCT05966090 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Quebec, Ontario, Florida.
Frequently Asked Questions
What is clinical trial NCT05966090 about?
NCT05966090 is a clinical study titled "A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults". To assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with HZ/su vaccine and its safety in older adults, aged \>=50 years of age.
What is the current status of trial NCT05966090?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 530 participants. The study started on 2023-07-28. Estimated completion is 2024-07-29.
What conditions does trial NCT05966090 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus Infections, Respiratory Syncytial Viruses.
What interventions are being tested in trial NCT05966090?
The interventions under investigation include: RSVPreF3 OA investigational vaccine (BIOLOGICAL), HZ/su vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05966090?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05966090 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
RECRUITING · Phase 3
-
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
ACTIVE NOT RECRUITING · Phase 3
-
Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
ACTIVE NOT RECRUITING · Phase 3
-
A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above
COMPLETED · Phase 3
-
A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control
COMPLETED · Phase 3
-
A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.
COMPLETED · Phase 3
Explore more on PlainTrial
Respiratory Syncytial Virus Infections
All registered trials for this condition
Respiratory Syncytial Viruses
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.